WO2011097582A3 - Treatment of arachidonate 12-lipoxygenase, 12r type (alox12b) related diseases by inhibition of natural antisense transcript to alox12b - Google Patents

Treatment of arachidonate 12-lipoxygenase, 12r type (alox12b) related diseases by inhibition of natural antisense transcript to alox12b Download PDF

Info

Publication number
WO2011097582A3
WO2011097582A3 PCT/US2011/023931 US2011023931W WO2011097582A3 WO 2011097582 A3 WO2011097582 A3 WO 2011097582A3 US 2011023931 W US2011023931 W US 2011023931W WO 2011097582 A3 WO2011097582 A3 WO 2011097582A3
Authority
WO
WIPO (PCT)
Prior art keywords
alox12b
arachidonate
lipoxygenase
type
inhibition
Prior art date
Application number
PCT/US2011/023931
Other languages
French (fr)
Other versions
WO2011097582A2 (en
Inventor
Joseph Collard
Olga Khorkova Sherman
Original Assignee
Opko Curna Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Curna Llc filed Critical Opko Curna Llc
Publication of WO2011097582A2 publication Critical patent/WO2011097582A2/en
Publication of WO2011097582A3 publication Critical patent/WO2011097582A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense

Abstract

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Arachidonate 12-lipoxygenase, 12R type (ALOX12B), in particular, by targeting natural antisense polynucleotides of Arachidonate 12-lipoxygenase, 12R type (ALOX12B). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of ALOX12B.
PCT/US2011/023931 2010-02-08 2011-02-07 Treatment of arachidonate 12-lipoxygenase, 12r type (alox12b) related diseases by inhibition of natural antisense transcript to alox12b WO2011097582A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30218810P 2010-02-08 2010-02-08
US61/302,188 2010-02-08

Publications (2)

Publication Number Publication Date
WO2011097582A2 WO2011097582A2 (en) 2011-08-11
WO2011097582A3 true WO2011097582A3 (en) 2012-01-05

Family

ID=44356107

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/023931 WO2011097582A2 (en) 2010-02-08 2011-02-07 Treatment of arachidonate 12-lipoxygenase, 12r type (alox12b) related diseases by inhibition of natural antisense transcript to alox12b

Country Status (1)

Country Link
WO (1) WO2011097582A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9920317B2 (en) 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
AU2011325956B2 (en) 2010-11-12 2016-07-14 The General Hospital Corporation Polycomb-associated non-coding RNAs
CA2873794A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics Inc. Compositions and methods for modulating smn gene family expression
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
EA201492116A1 (en) 2012-05-16 2015-05-29 Рана Терапьютикс, Инк. COMPOSITIONS AND METHODS FOR MODULATING THE EXPRESSION OF MECP2
JP2015518713A (en) 2012-05-16 2015-07-06 ラナ セラピューティクス インコーポレイテッド Compositions and methods for modulating UTRN expression
CN104583398A (en) 2012-05-16 2015-04-29 Rana医疗有限公司 Compositions and methods for modulating gene expression
EP2850188A4 (en) 2012-05-16 2016-01-20 Rana Therapeutics Inc Compositions and methods for modulating hemoglobin gene family expression
WO2013173598A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating atp2a2 expression
CA2966044A1 (en) 2014-10-30 2016-05-06 The General Hospital Corporation Methods for modulating atrx-dependent gene repression
US10900036B2 (en) 2015-03-17 2021-01-26 The General Hospital Corporation RNA interactome of polycomb repressive complex 1 (PRC1)
CN112063746B (en) * 2020-09-27 2022-05-17 中国农业科学院油料作物研究所 SNP molecular marker located in peanut FAD2A gene promoter region and related to peanut oleic acid and linoleic acid content and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060223093A1 (en) * 2005-03-11 2006-10-05 Applera Corporation Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof
US20070248590A1 (en) * 2005-12-02 2007-10-25 Sirtris Pharmaceuticals, Inc. Modulators of CDC2-like kinases (CLKS) and methods of use thereof
US20090221620A1 (en) * 2008-02-20 2009-09-03 Celera Corporation Gentic polymorphisms associated with stroke, methods of detection and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060223093A1 (en) * 2005-03-11 2006-10-05 Applera Corporation Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof
US20070248590A1 (en) * 2005-12-02 2007-10-25 Sirtris Pharmaceuticals, Inc. Modulators of CDC2-like kinases (CLKS) and methods of use thereof
US20090221620A1 (en) * 2008-02-20 2009-09-03 Celera Corporation Gentic polymorphisms associated with stroke, methods of detection and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK 16 August 2009 (2009-08-16), "Homo sapiens arachidonate 12- lipoxygenase, 12R type (ALOX12B), RefSeqGene on chromosome 17", Database accession no. NG_007099 *
JULIA A. SEGRE.: "Epidermal barrier formation and recovery in skin disorders.", THE JOURNAL OF CLINICAL INVESTIGATION., vol. 116, no. 5, 2006, pages 1150 - 1158 *
MANDY HARTING, MD ET AL.: "Self-Healing Collodion Membrane and Mild Nonbullous Congenital Ichthyosiform Erythroderma Due to 2 Novel Mutations in the ALOX12B Gene.", ARCHIVES OF DERMATOLOGY., vol. 144, no. 3, 2008, pages 351 - 356 *

Also Published As

Publication number Publication date
WO2011097582A2 (en) 2011-08-11

Similar Documents

Publication Publication Date Title
WO2011097582A3 (en) Treatment of arachidonate 12-lipoxygenase, 12r type (alox12b) related diseases by inhibition of natural antisense transcript to alox12b
WO2010129746A3 (en) Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
WO2010129861A3 (en) Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
WO2012054723A3 (en) Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
WO2010065787A3 (en) Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
WO2010151671A3 (en) Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
WO2011163499A3 (en) Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna
WO2011090741A3 (en) TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63
WO2011103528A3 (en) Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
WO2011085347A3 (en) Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
WO2010138806A3 (en) Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
WO2010148050A3 (en) Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
WO2011091390A3 (en) Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1
WO2012024478A3 (en) Treatment of nicotinamide phosphoribosyltransferase (nampt) related diseases by inhibition of natural antisense transcript to nampt
WO2012009402A3 (en) Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg
WO2011143640A3 (en) Treatment of par4 related diseases by inhibition of natural antisense transcript to par4
WO2011090740A3 (en) Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
WO2010107733A3 (en) Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
WO2011085066A3 (en) Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
WO2011038210A3 (en) Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
WO2010129799A3 (en) Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene
WO2011082409A3 (en) Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
WO2012047956A3 (en) Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
WO2010135329A3 (en) Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
WO2011019815A3 (en) Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11740500

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11740500

Country of ref document: EP

Kind code of ref document: A2